Document is current
Any future updates will be listed below
-
Authors
Burger, David M. https://orcid.org/0000-0001-7279-2818
Nijboer, Laura
Ghobreyal, Mira
Maertens, Johan
Blijlevens, Nicole
Hilbrands, Luuk
Baas, Marije C.
Ljungman, Per
Brüggemann, Roger J. M. https://orcid.org/0000-0002-7618-725X
- License Information
-
More Information
Article History
Accepted: 8 October 2024
First Online: 7 November 2024
Declarations
:
: No funding was received for this publication.
: D.M.B. is co-founder of Global DDI Solutions and received unrestricted research grants from Gilead, ViiV HealthCare, Pfizer and Merck. All payments were invoiced by the Radboudumc and paid to Radboudumc. J.M. has received research support from Pfizer and Gilead and has served as a consultant or speaker for Gilead, Pfizer, MSD, Cidara, Mundipharma, F2G, Amplyx, Basilea, Shionoghi, Synexis and Takeda. L.H. declares no interest with regards to this work. Outside of this work, he has served as consultant to and has received unrestricted research grants from Astellas Pharma, Chiesi, and Sandoz. All payments were invoiced by the Radboudumc and paid to Radboudumc. R.J.M.B. declares no interest with regards to this work. Outside of this work, he has served as consultant to and has received unrestricted research grants from Astellas Pharma Inc., F2G, Gilead sciences, Merck Sharpe and Dohme Corp., Cidara, Mundipharma Inc. and Pfizer Inc. All payments were invoiced by the Radboudumc and paid to Radboudumc. L.N., M.G., N.B., P.L. and M.C.B. have not declared a conflict of interest.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: DB performed the initial selection of papers, which were double checked by MG and LN. All authors reviewed draft versions of the paper and the tables, and all authors approved the final version of the paper.
